Current Headlines

  1. Researchers Develop Faster Cancer Drug Discovery Platform
    10/2/2014

    University of Michigan researchers have developed a new method for identifying potential cancer therapeutics that speeds up the traditionally slow drug discovery process. Using this new platform, the researchers were able to identify a novel antibody which is currently being evaluated as a potential treatment for breast, ovarian, and other cancers.

  2. Puma Biotech Posts Positive Phase 2 Data For NSCLC Drug
    10/1/2014

    Development stage biopharmaceutical firm Puma Biotechnology reported positive early results from its Phase 2 trial investigating PB272 (neratinib) for the treatment of patients with HER2-mutated non-small cell lung cancer (NSCLC).

  3. Pfizer And Kyowa Hakko Kirin To Combine Immuno-Oncology Drugs
    10/1/2014

    Pfizer announced that it has entered an agreement with Kyowa Hakko Kirin to explore the potential of the immuno-oncology combination of Kyowa’s mogamulizumab and Pfizer’s antibody PF-05082566 in patients with solid tumors.

  4. Atara Biotherapeutics, MSK Enter Into New Immunotherapy Alliance
    10/1/2014

    California based biotech company, Atara Biotherapeutics, has entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development and commercialization of allogeneic T-cell therapies, which are currently being investigated in human clinical trials for the treatment of certain cancers and persistent viral infections.

  5. Glialogix Receives National Multiple Sclerosis Society Funding For Treatment Development
    10/1/2014

    Glialogix announced that it had signed a research agreement with the non-profit Fast Forward, a part of the National Multiple Sclerosis Society (NMSS), which would fund continued development of GLX1112, a neuroprotective oral therapy with the potential to treat progressive MS. 

  6. Meissner To Exhibit At ISPE’s Annual Product Show At Gillette Stadium
    10/1/2014

    Meissner will be hosting attendees in booth #2164 at the ISPE Boston Chapter’s 23rd Annual Product Show. The event will run from 12:00 pm – 7:30 pm on Wednesday, October 1, 2014, at Gillette Stadium, Foxborough, MA.

  7. Rare Antibodies May Be Key To Future HIV Vaccine
    9/30/2014

    A team of researchers from The Scripps Research Institute (TSRI) reported their findings about a single family of antibodies that could adapt to fight the elusive HIV virus and its different strains. Their discovery may one day provide the key to designing an effective HIV vaccine in the future.

  8. Researchers Identify Potential Treatment For Deadly Kidney Disease
    9/30/2014

    Biochemists at UCLA have uncovered a potential treatment for PH1, a rare and potentially deadly genetic kidney disease in children.

  9. U.K. Researchers On Track To Develop Enzyme-Blocking Cancer, Alzheimer’s “Wonder Drug”
    9/30/2014

    Scientists at the Imperial College London have discovered a molecule with the potential to block the activity of an enzyme that is responsible for the progression of disease. Further investigation and development could yield a revolutionary and potent treatment for serious diseases, such as cancer, Alzheimer’s disease, and diabetes.

  10. Novo Nordisk To Focus On Obesity With New Seattle Research Unit
    9/30/2014

    Novo Nordisk is focusing efforts on obesity treatments and is building a new obesity research unit in Seattle, WA. The company announced the initiative in a press release. The Novo Nordisk Obesity Research Unit will initially employ 10 people, reaching 60 by the end of 2016. The new center will concentrate on basic research and treatments for obesity. Mads Krogsgaard Thomsen, EVP and CSO at Novo Nordisk, said, “Our ambition is to drive scientific progress in the obesity disease area and through this, identify and develop new treatment options for people with obesity.”

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.